Trust Company’s Legend Biotech LEGN Stock Holding History

Trust Company’s Portfolio LEGN Stock Details LEGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$318	Hold	11	–	–	﹤0.01%	839
2026 Q1	$199	Hold	11	–	–	﹤0.01%	871
2025 Q4	$239	Buy	+11	New	+$315	﹤0.01%	856

Other funds holding LEGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Trust Company's LEGN Position: Q2 2026 in Review

Trust Company held its Legend Biotech (LEGN) position steady in Q2 2026 at 11 shares worth $318. The position accounts for ﹤0.01% of the portfolio, ranked #839.

Trust Company first reported a position in LEGN in Q4 2025 and has held it in 3 quarters since. 218 funds tracked by Wall St. Rank hold LEGN as of Q2 2026.

Trust Company held 11 shares of Legend Biotech worth $318 as of Q2 2026.
Trust Company left its Legend Biotech share count unchanged in Q2 2026.
Legend Biotech made up ﹤0.01% of Trust Company's portfolio in Q2 2026, its #839 holding.
Trust Company first reported a position in Legend Biotech in Q4 2025 and has held it in 3 quarters since.
218 funds tracked by Wall St. Rank held Legend Biotech as of Q2 2026.

Based on Trust Company's 13F filing for Q2 2026, filed 10 Jul 2026.